Tradestie Institutional Equity Comparison Engine
RCEL vs BMRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
RCEL Overall Edge
RCEL Captures Institutional Edge (4โ0 Pillars ยท 8โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Avita Medical, Inc. Common Stock (RCEL) driven by superior Valuation, Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, RCEL trades at 10.3x Forward P/E with -33.9% operating margin (+53.1% YoY revenue) versus BMRA at N/M Forward P/E and -125.2% operating margin (-8.3% YoY). In options structure, RCEL sits in SURGE (5th %ile IV; Dealer Gamma Walls on Pro) against BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
RCEL
RCEL 10.3x vs BMRA N/M Fwd P/E
Growth & Margin Winner
RCEL
Op Margin -33.9% vs -125.2% ยท YoY +53.1% vs -8.3%
Momentum & Technical Winner
RCEL
1Y +311.9% vs -46.9% ยท 52W Pos 80% vs 4%
Options & Structure Winner
RCEL
SURGE (5th %ile IV) vs UNCLASSIFIED (N/A IV)
RCEL
NASDAQ
Avita Medical, Inc. Common Stock
Surgical & Medical Instruments & Apparatus
$15.40
-1.44% 1D
Market Cap
$509.0M
1M Return
+18.14%
1Y Return
+311.9%
Forward P/E
10.3x
Unified AI Score
53.1 / 100
HOLD
Tech 40.0
Fund 50.0
Flow 71.0
Mom 46.0
BMRA
NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap
$6.0M
1M Return
-28.19%
1Y Return
-46.86%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
RCEL +311.9%
BMRA -46.86%
Spread: +358.76 pp (RCEL Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | RCEL Revenue | BMRA Revenue | RCEL Op. Margin | BMRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $10M | $10M | -466.4% | -46.4% | BMRA |
| FY2020 | $10M | $10M | -299.2% | -41.0% | BMRA |
| FY2021 | $30M | $10M | -90.8% | -104.2% | RCEL |
| FY2022 | $30M | $20M | -79.9% | -24.0% | BMRA |
| FY2023 | $50M | $10M | -85.1% | -135.3% | RCEL |
| FY2024 | $60M | $10M | -88.1% | -117.6% | RCEL |
| FY2025 | $70M | $10M | -59.4% | -96.7% | RCEL |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | RCEL | BMRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $509.0M | $6.0M | Larger Scale | RCEL |
| Trailing P/E Ratio Valuation | 10.3x | N/M | Lower Multiple | RCEL |
| Forward P/E Ratio Valuation | 10.3x | N/M | Lower Multiple | RCEL |
| Revenue Growth (YoY) Growth | +53.1% | -8.3% | Higher Growth | RCEL |
| Operating Margin (TTM) Profitability | -33.9% | -125.2% | Higher Margin | RCEL |
| Net Profit Margin Profitability | -42.6% | -115.5% | Higher Margin | RCEL |
| Return on Equity (ROE) Capital Efficiency | -1746.3% | -113.8% | Higher ROE | BMRA |
| 52-Week Range Position Momentum | 80% ($3โ$18) | 4% ($1โ$3) | Stronger Trend | RCEL |
| Beta / 30D Volatility Risk Regime | 1.65ฮฒ ยท 70% Vol | 0.67ฮฒ ยท 62% Vol | Lower Realized Risk | BMRA |
| Unified Institutional Score Composite Signal | 53.1 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | RCEL |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full RCEL vs BMRA Buy Guide
RCEL
SURGE
13d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
BMRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither RCEL nor BMRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.